The second part of our conversation with Craig Burton, MBA, executive director of the Biosimilars Council, a trade and ...

The treatment landscape of Inflammatory Bowel Disease (IBD) has undergone a significant transformation over the past two ...

In November, Amneal received FDA approval for exenatide, its first generic injectable glucagon-like peptide-1 (GLP-1) agonist ...

FYB202 is an interleukin inhibitor that can be used in dermatology to treat psoriasis and in gastroenterology to treat chronic inflammatory bowel disease. The biosimilar received marketing ...

An ustekinumab biosimilar to Stelara launched in France, completing its rollout across 5 major European markets and paving the way for its US launch. Celltrion’s Stelara biosimilar ustekinumab ...

Amgen's Wezlana leading ustekinumab biosimilar launches, potentially driving savings and access, as highlighted by Dracey ...

Shares of Formycon AG (ETR:FYB) tumbled 39.16% on Monday following the company's announcement regarding the termination of ...

J&J JNJ stock has risen more than 6% in the past month. The reason behind the increase was a strong-than-expected ...

In this episode of Not So Different, host Skylar Jeremias covers the latest biosimilar developments, including new FDA ...